Comparison

Zepbound vs Mounjaro

Zepbound and Mounjaro are the same medication — tirzepatide — made by Eli Lilly, at the same doses (2.5 mg to 15 mg weekly injections). The only differences are the brand name, the FDA indication (Zepbound for chronic weight management and obstructive sleep apnea; Mounjaro for type 2 diabetes), the pen device design, and insurance coverage rules. Understanding this distinction is critical for patients whose insurer covers one but not the other.

4.3(112 ratings)

Quick Answer

Zepbound and Mounjaro are identical drugs — both are tirzepatide by Eli Lilly at the same 2.5–15 mg doses. The difference is FDA indication: Mounjaro is approved for type 2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea. The pen device differs cosmetically. Insurance coverage rules vary — many weight-management plans cover Zepbound but not Mounjaro for obesity, even though the molecule is the same.

Head-to-Head Comparison

Criteria	Zepbound	Mounjaro
Active ingredient	Tirzepatide (dual GIP/GLP-1 receptor agonist)	Tirzepatide (dual GIP/GLP-1 receptor agonist) — identical
FDA indication	Chronic weight management in adults with obesity/overweight + comorbidities; obstructive sleep apnea (Dec 2024)	Type 2 diabetes mellitus (adjunct to diet and exercise)
Available doses	2.5, 5, 7.5, 10, 12.5, 15 mg weekly injection pens	2.5, 5, 7.5, 10, 12.5, 15 mg weekly injection pens — identical
Pen device	Zepbound single-dose autoinjector pen (purple/teal design)	Mounjaro single-dose autoinjector pen (different color design)
US list price (2026)	~$1,060–$1,200/month	~$1,060–$1,200/month — same pricing
Insurance coverage for obesity	Covered under obesity/weight management benefits if available	NOT covered for obesity — only for T2D; insurers deny off-label obesity use
Insurance coverage for T2D	NOT the labeled indication for T2D — may face prior auth issues	Covered under T2D diabetes management benefits
Manufacturer savings card	Lilly Zepbound Savings Card: eligible patients may pay as low as $25/month	Lilly Mounjaro Savings Card: eligible patients may pay as low as $25/month
Efficacy difference	Identical — same molecule, same dose, same pharmacokinetics	Identical — no clinical difference between the two brands
Side effect profile	Identical — nausea, diarrhea, constipation, vomiting during titration	Identical — same molecule means same side effects

When to Choose Each

Choose Zepbound

Adults with obesity or overweight with a weight-related comorbidity (hypertension, T2D, dyslipidemia, sleep apnea) who need tirzepatide and have weight management drug coverage, or patients with obstructive sleep apnea.

Choose Mounjaro

Adults with type 2 diabetes who need tirzepatide and have diabetes drug coverage. Also the appropriate brand to request if your insurer only covers tirzepatide under a T2D indication.

Verdict

Zepbound and Mounjaro are pharmacologically identical — the same tirzepatide molecule at the same doses. The practical difference is entirely about insurance, regulatory indication, and pen branding. Patients using tirzepatide for weight management should be prescribed Zepbound (the obesity indication) to maximize insurance coverage under weight-management benefits. Patients using tirzepatide for type 2 diabetes should be prescribed Mounjaro. Some patients with both T2D and obesity may find one covered and not the other — work with your prescribing physician and insurer to determine which brand your plan covers. Never switch between Mounjaro and Zepbound without consulting your provider and checking formulary coverage.

References

Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) (2022) — PubMed
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) (2021) — PubMed
Tirzepatide once weekly for the treatment of obesity in adults with type 2 diabetes (SURMOUNT-2) (2023) — PubMed
Tirzepatide for moderate-to-severe obstructive sleep apnea (SURMOUNT-OSA) (2024) — PubMed
GIP and GLP-1 as incretin hormones: lessons from single and dual incretin receptor knockouts in mice (2023) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Henry Meds

Most Peptides

4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider

✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available

✓Repair peptides including BPC-157 and TB-500

✗Higher starting price due to comprehensive programs

✗More complex onboarding including lab work requirements

Ro Body

Best Value

4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo

✓Dedicated health coach included in program

✓Strong clinical protocols with lab-work integration

✗Narrower peptide offering — GLP-1s only

✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage

✓Evidence-based one-year program with structured milestones

✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)

✗Annual program commitment required

✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees

✓Strong community and peer support features

✓Certified health coaches with regular check-ins

✗Medication billed separately from program fee — total cost can be higher

✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Hims & HersMost Popular

From $199/moLearn More →

Henry MedsMost Peptides

From $249/moLearn More →

Ro BodyBest Value

From $149/moLearn More →

Frequently Asked Questions

Are Zepbound and Mounjaro the same drug?

Yes — Zepbound and Mounjaro are the exact same active ingredient (tirzepatide) at the same doses (2.5 mg through 15 mg), manufactured by Eli Lilly. The only differences are the brand name, the pen color and design, the FDA indication on the label, and how insurance companies categorize coverage. The pharmacological effects, weight loss, and side effects are clinically identical.

Can I use Mounjaro for weight loss if I don't have type 2 diabetes?

Mounjaro is FDA-approved only for type 2 diabetes. Using it off-label for weight loss in a non-diabetic patient is technically possible with a physician's prescription, but most insurers will not cover it for obesity when Zepbound (the labeled obesity indication) exists. Additionally, many prior authorization rules specifically require the approved brand for the covered condition. For weight loss in patients without T2D, Zepbound is the correct branded product to request.

Why does my insurance cover Mounjaro but not Zepbound (or vice versa)?

Insurance formularies treat Zepbound and Mounjaro as different products despite being the same molecule, because FDA labels and drug benefit categories differ. Plans with pharmacy benefits covering diabetes drugs may cover Mounjaro (T2D indication) but not Zepbound if they exclude obesity drugs. Conversely, plans with obesity benefit riders may cover Zepbound but not reimburse Mounjaro for weight loss. Work with your provider to get prior authorization using the brand that fits your plan's covered indications.

Which is cheaper — Zepbound or Mounjaro?

List prices are virtually identical — approximately $1,060–$1,200/month for both brands at equivalent doses (as of 2026). Both have Lilly savings cards that can reduce cost to $25/month for commercially insured patients. For uninsured patients, Lilly offers income-based assistance programs. Compounded tirzepatide from 503B facilities is typically $200–$500/month where legally available. Cost differences between the two brands in practice come down to insurance coverage, not list price.

Can Zepbound be prescribed for type 2 diabetes?

Zepbound is not FDA-approved for type 2 diabetes — Mounjaro carries that indication. A physician can technically prescribe Zepbound off-label for T2D, but this is uncommon and most insurers will not cover it under a T2D benefit when Mounjaro (the approved T2D brand) is available. If you have both T2D and obesity, discuss with your provider which brand your insurance will cover for your primary diagnosis.

Is the Zepbound pen the same as the Mounjaro pen?

The pens are functionally similar — both are single-use autoinjectors by Eli Lilly — but they have different color schemes and labeling. Zepbound pens have a distinct purple/teal design; Mounjaro pens have a different color. The injection mechanism, needle gauge, and fill volume are the same. Do not confuse the brands at a pharmacy — verify your prescription brand matches your dispensed medication.

Explore next

Peptides

Zepbound profile
Weight Loss & Diabetes

Guides

Tirzepatide dosage guide
Complete tirzepatide dosage chart with titration schedule, dose escalation timeline, reconstitution instructions for compounded forms, and side effect management strategies. Educational reference based on published clinical trial data.

More comparisons

Tools